These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32270866)

  • 21. WBSCR22 confers oxaliplatin resistance in human colorectal cancer.
    Yan D; Tu L; Yuan H; Fang J; Cheng L; Zheng X; Wang X
    Sci Rep; 2017 Nov; 7(1):15443. PubMed ID: 29133897
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sec62 promotes stemness and chemoresistance of human colorectal cancer through activating Wnt/β-catenin pathway.
    Liu X; Su K; Sun X; Jiang Y; Wang L; Hu C; Zhang C; Lu M; Du X; Xing B
    J Exp Clin Cancer Res; 2021 Apr; 40(1):132. PubMed ID: 33858476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eukaryotic initiation factor 4A2 promotes experimental metastasis and oxaliplatin resistance in colorectal cancer.
    Chen ZH; Qi JJ; Wu QN; Lu JH; Liu ZX; Wang Y; Hu PS; Li T; Lin JF; Wu XY; Miao L; Zeng ZL; Xie D; Ju HQ; Xu RH; Wang F
    J Exp Clin Cancer Res; 2019 May; 38(1):196. PubMed ID: 31088567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circular RNA protein tyrosine kinase 2 (circPTK2) promotes colorectal cancer proliferation, migration, invasion and chemoresistance.
    Jiang Z; Hou Z; Liu W; Yu Z; Liang Z; Chen S
    Bioengineered; 2022 Jan; 13(1):810-823. PubMed ID: 34974791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EVs delivery of miR-1915-3p improves the chemotherapeutic efficacy of oxaliplatin in colorectal cancer.
    Xiao Z; Liu Y; Li Q; Liu Q; Liu Y; Luo Y; Wei S
    Cancer Chemother Pharmacol; 2021 Dec; 88(6):1021-1031. PubMed ID: 34599680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. miR-193a-5p as a promising therapeutic candidate in colorectal cancer by reducing 5-FU and Oxaliplatin chemoresistance by targeting CXCR4.
    Azar MRMH; Aghazadeh H; Mohammed HN; Sara MRS; Hosseini A; Shomali N; Tamjidifar R; Tarzi S; Mansouri M; Sarand SP; Marofi F; Akbari M; Xu H; Shotorbani SS
    Int Immunopharmacol; 2021 Mar; 92():107355. PubMed ID: 33429333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IRF-1 mediated long non-coding RNA PVT1-214 promotes oxaliplatin resistance of colorectal cancer via miR-128 inhibition.
    Tong D; Zou E; Bai L; Ma J; Guo N; Wang H; Jiang L
    J BUON; 2020; 25(5):2205-2214. PubMed ID: 33277837
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LncRNA-NEF suppressed oxaliplatin resistance and epithelial-mesenchymal transition in colorectal cancer through epigenetically inactivating MEK/ERK signaling.
    Shi CJ; Xue ZH; Zeng WQ; Deng LQ; Pang FX; Zhang FW; Fu WM; Zhang JF
    Cancer Gene Ther; 2023 Jun; 30(6):855-865. PubMed ID: 36782047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transcription factor B-MYB activates lncRNA CCAT1 and upregulates SOCS3 to promote chemoresistance in colorectal cancer.
    Liu F; Wang Y; Cao Y; Wu Z; Ma D; Cai J; Sha J; Chen Q
    Chem Biol Interact; 2023 Apr; 374():110412. PubMed ID: 36812959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elevating H3K27me3 level sensitizes colorectal cancer to oxaliplatin.
    Wang Q; Chen X; Jiang Y; Liu S; Liu H; Sun X; Zhang H; Liu Z; Tao Y; Li C; Hu Y; Liu D; Ye D; Liu Y; Wang M; Zhang X
    J Mol Cell Biol; 2020 Feb; 12(2):125-137. PubMed ID: 31065671
    [TBL] [Abstract][Full Text] [Related]  

  • 31. lncRNA MIR600HG induces the proliferation and invasion of colorectal cancer cells via regulating miR-144-3p/KIF3A.
    Huang Y; Wang L; Liu D
    Int Immunopharmacol; 2022 Jul; 108():108686. PubMed ID: 35378445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PRDM14 promotes malignant phenotype and correlates with poor prognosis in colorectal cancer.
    Igarashi H; Taniguchi H; Nosho K; Ishigami K; Koide H; Mitsuhashi K; Okita K; Takemasa I; Imai K; Nakase H
    Clin Transl Oncol; 2020 Jul; 22(7):1126-1137. PubMed ID: 31741141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Wnt/β-catenin signalling activates IMPDH2-mediated purine metabolism to facilitate oxaliplatin resistance by inhibiting caspase-dependent apoptosis in colorectal cancer.
    Huang Y; Chan S; Chen S; Liu X; Li M; Zheng L; Dong Z; Yang Z; Liu Z; Zhou D; Zhang X; Zhang B
    J Transl Med; 2024 Feb; 22(1):133. PubMed ID: 38310229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor suppressor circPDE4D inhibits the progression of colorectal cancer and regulates oxaliplatin chemoresistance.
    Li J; Lv J; Chen Y; Li L
    Gene; 2023 May; 864():147323. PubMed ID: 36858188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retraction: MIR600HG suppresses metastasis and enhances oxaliplatin chemosensitivity by targeting ALDH1A3 in colorectal cancer.
    Biosci Rep; 2024 Sep; 44(9):. PubMed ID: 39254595
    [No Abstract]   [Full Text] [Related]  

  • 36. SNHG4-mediated PTEN destabilization confers oxaliplatin resistance in colorectal cancer cells by inhibiting ferroptosis.
    Li SQ; Xu WT; Yin YX; Wei HT; Li KZ; Xie MZ; Lv F; Xie LY; Hu BL
    Apoptosis; 2024 Jun; 29(5-6):835-848. PubMed ID: 38573492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostaglandin F
    Wang YJ; Xie XL; Liu HQ; Tian H; Jiang XY; Zhang JN; Chen SX; Liu T; Wang SL; Zhou X; Jin XX; Liu SM; Jiang HQ
    World J Gastroenterol; 2023 Oct; 29(39):5452-5470. PubMed ID: 37900995
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LncRNA NEAT1 promotes the tumorigenesis of colorectal cancer by sponging miR-193a-3p.
    Yu HM; Wang C; Yuan Z; Chen GL; Ye T; Yang BW
    Cell Prolif; 2019 Jan; 52(1):e12526. PubMed ID: 30407674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long non-coding RNA TP73-AS1 sponges miR-194 to promote colorectal cancer cell proliferation, migration and invasion via up-regulating TGFα.
    Cai Y; Yan P; Zhang G; Yang W; Wang H; Cheng X
    Cancer Biomark; 2018; 23(1):145-156. PubMed ID: 30010111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNA-497 inhibits tumor growth and increases chemosensitivity to 5-fluorouracil treatment by targeting KSR1.
    Wang L; Jiang CF; Li DM; Ge X; Shi ZM; Li CY; Liu X; Yin Y; Zhen L; Liu LZ; Jiang BH
    Oncotarget; 2016 Jan; 7(3):2660-71. PubMed ID: 26673620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.